165 related articles for article (PubMed ID: 29440684)
1. Characterization of
Willekens SMA; Joosten L; Boerman OC; Brom M; Gotthardt M
Sci Rep; 2018 Feb; 8(1):2948. PubMed ID: 29440684
[TBL] [Abstract][Full Text] [Related]
2. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of a
Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM
Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts.
Santini C; Kuil J; Bunschoten A; Pool S; de Blois E; Ridwan Y; Essers J; Bernsen MR; van Leeuwen FW; de Jong M
J Nucl Med; 2016 Aug; 57(8):1289-95. PubMed ID: 27127222
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
7. Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography.
Eriksson O; Velikyan I; Haack T; Bossart M; Evers A; Lorenz K; Laitinen I; Larsen PJ; Plettenburg O; Johansson L; Pierrou S; Wagner M
Diabetes; 2021 Apr; 70(4):842-853. PubMed ID: 33547046
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.
Joosten L; Brom M; Schäfer MKH; Boerman OC; Weihe E; Gotthardt M
Sci Rep; 2017 May; 7(1):1751. PubMed ID: 28496188
[TBL] [Abstract][Full Text] [Related]
9. Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand.
Yaqub T; Tikhonova IG; Lättig J; Magnan R; Laval M; Escrieut C; Boulègue C; Hewage C; Fourmy D
Mol Pharmacol; 2010 Apr; 77(4):547-58. PubMed ID: 20061446
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
11. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
12. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
13. GIP1-39, a novel insulinotropic peptide form and aspects on its mechanism of action.
Xie L; Lu J; Ostenson CG; Xu T; Chen ZW
Regul Pept; 2004 Sep; 121(1-3):107-12. PubMed ID: 15256280
[TBL] [Abstract][Full Text] [Related]
14. Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations.
Tikhele SH; Pissurlenkar RR; Srivastava S; Saran A; Coutinho EC
J Pept Sci; 2010 Aug; 16(8):383-91. PubMed ID: 20607844
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
16. Alternative form of glucose-dependent insulinotropic polypepide and its physiology.
Fujita Y; Yanagimachi T; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):33-7. PubMed ID: 27186353
[TBL] [Abstract][Full Text] [Related]
17. Human GIP(3-30)NH
Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
[TBL] [Abstract][Full Text] [Related]
18.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
